当前的实验室测试实践不匹配维修缺乏和微卫星不稳定性测试：基于调查的当前实验室实践的评论
Current laboratory testing practices for mismatch repair deficiency and microsatellite instability testing: A survey-based review of current laboratory practices
影响因子:1.90000
分区:医学4区 / 病理学3区
发表日期:2025 Jan 28
作者:
Amy L Austin, Russell R Broaddus, Rhona J Souers, Megan E Kane, Ravindra Kolhe, Dylan V Miller, Joel T Moncur, Shakti Ramkissoon, Laura J Tafe, Dimitri G Trembath, Rondell P Graham
摘要
描述使用美国病理学家学院（CAP）MSI/MMR能力测试计划在2022年在2022年发布MSI/MMR实践指南之前使用美国病理学家学院（CAP）MSI/MMR能力测试计划在实验室中进行不匹配修复（MMR）和微卫星不稳定性（MSI）测试实践审查了不同实践环境中的542个实验室。问卷包含21个有关进行测试的测试类型，用于测试的标本/肿瘤类型的问题以及检查点阻断疗法的临床实践。与国际实验室相比，MSI/MMR的内科实验室测试（P = .04）和学术医院/医疗中心测试的频率更高。最常用的测试方式是免疫组织化学，其次是聚合酶链反应，然后是下一代测序。大多数实验室（72.6％; 347/478）报道了对具有高MSI或MMR缺陷率的患者使用免疫检查点抑制剂疗法的认识。结果证明了在CAP/AMP最佳实践指南，强大的实验室差异之前，实验室中MMR和MSI测试的状态。这些发现表明了共识准则的重要性，并在实施后提供了比较的基准。版权所有。有关商业重复使用，请联系reprints@oup.com，以获取转载和翻译权以进行转载。所有其他权限都可以通过我们的restrimlink服务通过我们网站上文章页面上的“权限链接”获得 - 有关更多信息，请联系journals.permissions.permissions@oup.com。
Abstract
To describe mismatch repair (MMR) and microsatellite instability (MSI) testing practices in laboratories using the College of American Pathologists (CAP) MSI/MMR proficiency testing programs prior to the 2022 publication of the MSI/MMR practice guidelines copublished by CAP and the Association of Molecular Pathology (AMP).Data from supplemental questionnaires provided with the 2020-B MSI/MMR programs to 542 laboratories across different practice settings were reviewed. Questionnaires contained 21 questions regarding the type of testing performed, specimen/tumor types used for testing, and clinical practices for checkpoint blockade therapy.Domestic laboratories test for MSI/MMR more often than international laboratories (P = .04) and academic hospitals/medical centers test more frequently than nonhospital sites/clinics (P = .03). The most commonly used testing modality is immunohistochemistry, followed by polymerase chain reaction, then next-generation sequencing. Most laboratories (72.6%; 347/478) reported awareness of the use of immune checkpoint inhibitor therapy for patients with high MSI or MMR-deficient results.The results demonstrate the state of MMR and MSI testing in laboratories prior to the publication of the CAP/AMP best practice guidelines, highlighting differences between various laboratory types. The findings indicate the importance of consensus guidelines and provide a baseline for comparison after their implementation.© The Author(s) 2024. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.